[EN] CARBONYL LINKED BICYCLIC HETEROARYL N-BENZIMIDAZOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS [FR] N-BENZIMIDAZOLES HÉTÉROARYLES BICYCLIQUES LIÉS À DU CARBONYLE ET ANALOGUES UTILISÉS EN TANT QU'INHIBITEURS DE TOLÉRANCE AUX ANTIBIOTIQUES
[EN] CARBONYL LINKED BICYCLIC HETEROARYL N-BENZIMIDAZOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS [FR] N-BENZIMIDAZOLES HÉTÉROARYLES BICYCLIQUES LIÉS À DU CARBONYLE ET ANALOGUES UTILISÉS EN TANT QU'INHIBITEURS DE TOLÉRANCE AUX ANTIBIOTIQUES
[EN] CARBONYL LINKED BICYCLIC HETEROARYL N-BENZIMIDAZOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS<br/>[FR] N-BENZIMIDAZOLES HÉTÉROARYLES BICYCLIQUES LIÉS À DU CARBONYLE ET ANALOGUES UTILISÉS EN TANT QU'INHIBITEURS DE TOLÉRANCE AUX ANTIBIOTIQUES
申请人:SPERO THERAPEUTICS INC
公开号:WO2016040764A1
公开(公告)日:2016-03-17
The disclosure provides compounds and pharmaceutical compositions of includes carbonyl linked bicyclic heteroaryl N-benzimidazole compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.